フルオシノニド
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2012/10/03 18:19:45」(JST)
[Wiki en表示]
Fluocinonide
|
Systematic (IUPAC) name |
6α,9-difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone,21-acetate |
Clinical data |
Trade names |
Lidex |
AHFS/Drugs.com |
Micromedex Detailed Consumer Information |
MedlinePlus |
a601054 |
Pregnancy cat. |
C |
Legal status |
Prescription Only (S4) (AU) POM (UK) ℞-only (US) |
Routes |
topical |
Pharmacokinetic data |
Metabolism |
hepatic |
Identifiers |
CAS number |
356-12-7 |
ATC code |
C05AA11 D07AC08 |
PubChem |
CID 9642 |
DrugBank |
DB01047 |
ChemSpider |
9265 Y |
UNII |
2W4A77YPAN Y |
KEGG |
D00325 Y |
ChEMBL |
CHEMBL1501 Y |
Chemical data |
Formula |
C26H32F2O7 |
Mol. mass |
494.525 g/mol |
SMILES
- O=C(OCC(=O)[C@]45OC(O[C@@H]5C[C@@H]2[C@@]4(C[C@H](O)[C@]3(F)[C@]/1(/C=C\C(=O)\C=C\1[C@@H](F)C[C@@H]23)C)C)(C)C)C
|
InChI
-
InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1 Y
Key:WJOHZNCJWYWUJD-IUGZLZTKSA-N Y
|
Y (what is this?) (verify)
|
Fluocinonide (Fluonex, Lidex, Lidex-E, Lonide, Lyderm, and Vanos)[1] is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort.
The usual prescription concentration is 0.05% as a topical cream, ointment, or gel. The application area should normally not be covered after application. In certain cases, the physician may recommend the use of an occlusive dressing after application to increase the rate and depth of absorption. The frequency of application depends on the condition being treated and the area affected, but most often it should be applied twice a day.
Fluocinonide ranks as a "high-potency" (second-highest rank) topical corticosteroid. Minimal amounts should be used for a minimal length of time to avoid the occurrence of adverse effects.[2]
Fluocinonide should not be used if infection is present. It should not be applied to the eyes or to sensitive areas such as the genitals or anus.
A common potential adverse effect is skin atrophy (thinning of the skin). Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis (HPA) suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Fluocinonide should be used with caution when treating children, pregnant women, nursing mothers, and anyone using the medication for longer than two weeks.
Fluocinonide is used in veterinary medicine. It is a treatment for allergies in dogs.[3] Natural systemic cortisol concentrations can be suppressed for weeks after one week of topical exposure.[4]
References
- ^ MedlinePlus Drug Information: Fluocinonide Topical
- ^ Donald Y M Leung et al., "Disease management of atopic dermatitis: a practice parameter," Annals of Allergy, Asthma, & Immunology, Vol. 79, September 1997; http://www.jcaai.readyportal.net/file_depot/0-10000000/20000-30000/27387/folder/63948/Atopic_Derm1997.pdf
- ^ Dog Allergies www.squidoo.com/dogallergy
- ^ Zenoble RD, Kemppainen RJ, "Adrenocortical suppression by topically applied corticosteroids in healthy dogs." J Am Vet Med Assoc. 1987 Sep 15;191(6):685-8. http://www.ncbi.nlm.nih.gov/pubmed/2824410
Vasoprotectives (C05)
|
|
Antihemorrhoidals for topical use |
corticosteroids (Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Fluocortolone, Dexamethasone, Fluocinolone acetonide, Fluocinonide)
local anesthetics (Lidocaine, Tetracaine, Benzocaine, Dibucaine, Procaine, Oxetacaine, Pramocaine)
other (Tribenoside)
|
|
Antivaricose therapy |
heparins or heparinoids for topical use (Organo-heparinoid, Sodium apolate, Heparin, Pentosan polysulfate)
sclerosing agents for local injection (Monoethanolamine oleate, Polidocanol, Invert sugar, Sodium tetradecyl sulfate, Phenol)
other (Calcium dobesilate)
|
|
Capillary stabilising agents |
bioflavonoids (Rutoside, Monoxerutin, Diosmin, Troxerutin, Hidrosmin) - other (Tribenoside, Etamsylate)
|
|
|
anat(a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot
|
noco/syva/cong/lyvd/tumr, sysi/epon, injr
|
proc, drug(C2s+n/3/4/5/7/8/9)
|
|
|
|
Corticosteroids – glucocorticoids and mineralocorticoids (H02)
(also A07EA, C05AA, D07, D10AA, R01AD, R03BA, S01BA, S02B, and S03B)
|
|
Mineralocorticoids
(3-one, 4-ene,
no FG at 16) |
- Pregnenedione: ALDOSTERONE
- 11-DEOXYCORTICOSTERONE
- HALOGENATED AT 9: Fludrocortisone
|
|
Glucocorticoids
(3-one, 4-ene,
11-FG,
17-hydroxy) |
Pregnene
|
|
|
Pregnenedione
(+20-one)
|
- HYDROCORTISONE/CORTISOL# (Hydrocortisone aceponate
- Hydrocortisone buteprate
- Hydrocortisone butyrate)
- Budesonide
- Ciclesonide
- Deflazacort
- Medrysone
- Tixocortol
- HALOGENATED AT 6: Cloprednol
- HALOGENATED, WITH FG AT 16: Halcinonide
|
|
Pregnadiene (+1-ene)
|
- Rimexolone
- HALOGENATED, WITH FG AT 16: Flunisolide
- Triamcinolone
- Amcinonide
- Fluocinolone acetonide (Fluocinonide)
|
|
Pregnadienediol
(+21-hydroxy)
|
- Prednisone (Meprednisone)
- HALOGENATED AT 9: Fluorometholone
- HALOGENATED, WITH FG AT 16: Fluocortolone (Clocortolone
- Diflucortolone
- Fluocortin)
- Desoximetasone
|
|
Pregnadienetriol
(+11-hydroxy)
|
- Prednisolone# (Methylprednisolone
- Methylprednisolone aceponate
- Prednicarbate
- Prednylidene)
- Desonide
- HALOGENATED: Fluprednisolone (Difluprednate
- Fluperolone)
- HALOGENATED, WITH FG AT 16: Dexamethasone#
- Betamethasone (Clobetasol
- Clobetasone
- Diflorasone
- Halometasone
- Ulobetasol)
- Beclometasone
- Paramethasone
- Alclometasone
- Fluclorolone acetonide
- Flumetasone
- Fluprednidene
|
|
Pregnatriene
(+2-ene)
|
|
|
Androstene
|
- HALOGENATED, WITH FG AT 16: Fluticasone (Fluticasone propionate
- Fluticasone furoate)
|
|
Other/ungrouped
|
- HALOGENATED: Loteprednol
- HALOGENATED, WITH FG AT 16: Fludroxycortide
- Formocortal
- Mometasone furoate
|
|
|
Aldosterone antagonists |
- Spironolactone
- Eplerenone
- Potassium canrenoate
- Canrenone
|
|
Synthesis modifiers |
- Trilostane
- Carbenoxolone
- Aminoglutethimide
- Metyrapone
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
|
noco(d)/cong/tumr, sysi/epon
|
proc, drug (A10/H1/H2/H3/H5)
|
|
|
|
Glucocorticoids
|
|
Receptor |
|
|
Enzyme
(inhibitors) |
20,22-Desmolase
|
- 22-ABC
- 3,3′-Dimethoxybenzidine
- 3-Methoxybenzidine
- Aminoglutethimide
- Cyanoketone
- Danazol
- Etomidate
- Mitotane
- Trilostane
|
|
17α-Hydroxylase,
17,20-Lyase
|
- 22-ABC
- 22-Oxime
- Abiraterone
- Bifonazole
- Clotrimazole
- Cyanoketone
- Cyproterone
- Danazol
- Econazole
- Galeterone
- Gestrinone
- Isoconazole
- Ketoconazole
- L-39
- Liarozole
- LY-207,320
- MDL-27,302
- Miconazole
- Mifepristone
- Orteronel
- Pioglitazone
- Rosiglitazone
- Spironolactone
- Stanozolol
- SU-10,603
- TGF-β
- Tioconazole
- Troglitazone
- VN/87-1
- YM116
|
|
3β-HSD
|
- 4-MA
- Azastene
- Cyanoketone
- Danazol
- Epostane
- Genistein
- Gestrinone
- Metyrapone
- Norethisterone
- Oxymetholone
- Pioglitazone
- Rosiglitazone
- Trilostane
- Troglitazone
|
|
21-Hydroxylase
|
- Aminoglutethimide
- Amphenone B
- Bifonazole
- Clotrimazole
- Diazepam
- Econazole
- Genistein
- Isoconazole
- Ketoconazole
- Metyrapone
- Miconazole
- Midazolam
- Tioconazole
|
|
11β-Hydroxylase
|
- Aminoglutethimide
- Canrenone
- Etomidate
- Fadrozole
- FETO
- Ketoconazole
- Metomidate
- Metyrapone
- Mitotane
- Potassium canrenoate
- Spironolactone
- Trilostane
|
|
18-Hydroxylase
|
- Aminoglutethimide
- Canrenone
- FAD286
- Fadrozole
- Ketoconazole
- LCI699
- Metyrapone
- Mespirenone
- Potassium canrenoate
- Spironolactone
|
|
|
Other |
Endogenous
|
- Glucocorticoids: Corticosterone
- Cortisone
- Cortodoxone/Deoxycortisol
- Hydrocortisone/Cortisol
- Antiglucocorticoids: 17-Hydroxyprogesterone
- Deoxycorticosterone
- Pregnenolone
- Progesterone
- Precursors: Cholesterol
- 22R-Hydroxycholesterol
- 20α,22R-Dihydroxycholesterol
- Pregnenolone
- 17-Hydroxypregnenolone
- 17-Hydroxyprogesterone
- Progesterone
- Deoxycorticosterone
|
|
Indirect
|
- ACTH/Corticotropin
- CRH
- DHEA
- DHEA sulfate
- Plasma proteins (Transcortin, Albumin)
- Vasopressin
|
|
Procedures
|
- Adrenalectomy
- Hypophysectomy
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Investigation of solvolysis kinetics of new synthesized fluocinolone acetonide C-21 esters--an in vitro model for prodrug activation.
- Markovic BD, Dobricic VD, Vladimirov SM, Cudina OA, Savic VM, Karljikovic-Rajic KD.SourceDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia. bojan@pharmacy.bg.ac.rs
- Molecules (Basel, Switzerland).Molecules.2011 Mar 23;16(3):2658-71.
- In this study the solvolysis of newly synthesized fluocinolone acetonide C-21 esters was analysed in comparison with fluocinonide during a 24-hour period of time. The solvolysis was performed in an ethanol-water (90:10 v/v) mixture using the excess of NaHCO?. The solvolytic mixtures of each invest
- PMID 21441868
- Staphylococcal enterotoxin B causes proliferation of sensory C-fibers and subsequent enhancement of neurogenic inflammation in rat skin.
- Ohshima M, Miyake M, Takeda M, Kamijima M, Sakamoto T.SourceDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- The Journal of infectious diseases.J Infect Dis.2011 Mar 15;203(6):862-9. Epub 2011 Jan 20.
- BACKGROUND: Staphylococcal enterotoxin B (SEB) may be associated with the exacerbation of atopic dermatitis. We investigated whether SEB causes proliferation of sensory C-fibers and subsequent enhancement of plasma leakage induced by sensorineural stimulation in rat skin.METHODS: SEB was applied int
- PMID 21252260
Japanese Journal
- 虫垂瘻からのステロイド antedrug 注入療法を施行した潰瘍性大腸炎の3例
- 宮澤 智徳,岡本 春彦,谷 達夫,飯合 恒夫,畠山 勝義,本間 照,杉村 一仁,青柳 豊
- 日本大腸肛門病学会雑誌 59(4), 203-207, 2006-04-01
- ステロイド(以下SH)依存性の全大腸炎型の潰瘍性大腸炎(以下UC)3例に,虫垂瘻からのSH antedrug注入療法を施行したので報告する.症例1 21歳女性.腰椎麻酔下に虫垂瘻を作製しSH antedrugのフルオシノニド(以下FLU)注入療法を行った.緩解導入・維持が可能となり,25カ月後に本法を中止しその後も緩解を維持している.症例2 24歳女性.本法にてSH全身投与を中止できたが,施行後2 …
- NAID 10018167527
- 前田 美希代,石川 和宏,Amar Gajjar,藤井 正純,若林 俊彦,吉田 純,鍋島 俊隆
- 医療薬学 30(5), 330-334, 2004-05-10
- … The application of fluocinonide lotion to her scalp did not improve the symptoms, but the antihistaminic ebastine was effective. …
- NAID 110001166810
Related Links
- Fluocinonide (Fluonex, Lidex, Lidex-E, Lonide, Lyderm, and Vanos) is a potent glucocorticoid steroid used topically as an anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis. It relieves itching ...
- Fluocinonide comes in ointment, cream, solution, and gel in various strengths for use on the skin. It usually is applied two to four times a day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain ...
Related Pictures
★リンクテーブル★
[★]
- 英
- fluocinonide
- 商
- グリコベース、シマロン、ソルニム、トプシム、ビスコザール、フルオシノニド、ベスタゾン、Fluonex、Lidex
- 合成副腎皮質ホルモン剤の外用薬
- 糖質コルチコイド;強力な抗炎症作用;外用